Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

199 та иш

Иш: Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

  1. Neoantigens: promising targets for cancer therapy

    Na Xie, Guobo Shen, Wei Gao +3

    Шарҳ мақола20236 иқтибос
    ABI

  2. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

    Xinyi Xiao, Shengkang Huang, Sifei Chen +4

    Шарҳ мақола20215 иқтибос
    ABI

  3. Regulatory mechanisms of PD-1/PD-L1 in cancers

    Xin Lin, Kuan Kang, Pan Chen +5

    Мақола20245 иқтибос
    ABI

  4. Exploring treatment options in cancer: tumor treatment strategies

    Beilei Liu, Hongyu Zhou, Licheng Tan +2

    Шарҳ мақола20245 иқтибос
    ABI

  5. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

    Lei Peng, Giacomo Sferruzza, Luojia Yang +2

    Шарҳ мақола20245 иқтибос
    ABI

  6. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

    Levi J. Rupp, Kathrin Schumann, Kole T. Roybal +4

    Мақола20174 иқтибос
    ABI

  7. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

    Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis +6

    Мақола20174 иқтибос
    ABI

  8. CAR-T Cell Performance: How to Improve Their Persistence?

    Gina López-Cantillo, Claudia Urueña, Bernardo Camacho +1

    Шарҳ мақола20224 иқтибос
    ABI

  9. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells

    Miyuki Tanaka, Haruko Tashiro, Bilal Omer +9

    Мақола20173 иқтибос
    ABI

  10. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

    Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

    Мақола20173 иқтибос
    ABI

  11. Engineering CAR-T Cells for Next-Generation Cancer Therapy

    Mihe Hong, Justin Clubb, Yvonne Y. Chen

    Шарҳ мақола20203 иқтибос
    ABI

  12. Bispecific T‐cell engagers for cancer immunotherapy

    Amelia M. Huehls, Tiffany A. Coupet, Charles L. Sentman

    Шарҳ мақола20143 иқтибос
    ABI

  13. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

    Andriy Marusyk, Michalina Janiszewska, Kornélia Polyák

    Шарҳ мақола20203 иқтибос
    ABI

  14. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

    Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12

    Мақола20213 иқтибос
    ABI

  15. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

    Zhenguang Wang, Na Li, Kaichao Feng +14

    Мақола20213 иқтибос
    ABI

  16. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

    Changsong Qi, Jifang Gong, Jian Li +23

    Мақола20223 иқтибос
    ABI

  17. Long-term outcomes following CAR T cell therapy: what we know so far

    Kathryn M. Cappell, James N. Kochenderfer

    Шарҳ мақола20233 иқтибос
    ABI

  18. Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases

    Agata Kieliszek, Daniel Mobilio, Deepak Upreti +10

    Мақола20233 иқтибос
    ABI

  19. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

    Christine E. Brown, Behnam Badie, Michael E. Barish +14

    Мақола20152 иқтибос
    ABI

  20. Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

    Serena Perna, Daria Pagliara, Aruna Mahendravada +4

    Мақола20132 иқтибос
    ABI

  21. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

    Omkar U. Kawalekar, Roddy S. O’Connor, Joseph A. Fraietta +11

    Мақола20162 иқтибос
    ABI

  22. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells

    Lenka V. Hurton, Harjeet Singh, Amer Najjar +12

    Мақола20162 иқтибос
    ABI

  23. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

    Rachel Grosser, Leonid Cherkassky, Navin K. Chintala +1

    Шарҳ мақола20192 иқтибос
    ABI

  24. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

    Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9

    Мақола20132 иқтибос
    ABI

  25. The inducible caspase-9 suicide gene system as a “safety switch†to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

    Tessa Gargett, Michael P. Brown

    Шарҳ мақола20142 иқтибос
    ABI